Rigel Readies Tavalisse For Late-May Launch After FDA Approval

Rigel has its first US FDA approval for Tavalisse (fostamatinib) and plans to launch the drug for adults with immune thrombocytopenia (ITP) in late May, after working on the drug's development for more than a decade across multiple indications.

FDA approved background, 3D rendering, blue street sign

Rigel Pharmaceuticals Inc. has spent more than a decade developing Tavalisse (fostamatinib) across multiple indications and will finally launch the spleen tyrosine kinase (SYK) inhibitor in late May after the oral drug's US FDA approval on April 17 to treat adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a prior treatment.

Rigel President and CEO Raul Rodriguez told Scrip that the label "is exactly what we were hoping for" with a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip